In fact, although CD74 upregulation in the context of inflammation and cell stress has previously been observed in MHC II-negative cell types such as endothelial cells, cancer cells, or cardiomyocytes, the occurrence of CD74 in T cells is surprising, as T cells, which are MHC class II-negative themselves, are best known for their role in MHC-based peptide recognition from MHC-II+ antigen-presenting immune cells [21, 26–28]. This evidence concerns the gene CD74 and cancer.